Business
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE’s Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXT
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"image","alt":"Lixte Biotechnology Holdings, Inc.","displaySize":"","headline":null,"caption":"Lixte Biotechnology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FmV0Y7aYPvvleZjVNFp7LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6","width":275,"height":120}},"lazy":false},{"type":"text","content":"-Completes Two Financings, Raising $6.5 Million-","length":48,"tagName":"p"},{"type":"text","content":"-Regains Compliance for Continued Listing on Nasdaq-","length":52,"tagName":"p"},{"type":"text","content":"-Announces Management Changes; Adds Two New Board Members-","length":58,"tagName":"p"},{"type":"text","content":"-Re-Establishes Scientific Advisory Committee-","length":46,"tagName":"p"},{"type":"text","content":"-Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE’s Ongoing Clinical Trials with LB-100-","length":129,"tagName":"p"},{"type":"text","content":"-Launches New Pre-Clinical Study-","length":33,"tagName":"p"},{"type":"text","content":"PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities.","length":313,"tagName":"p"},{"type":"text","content":"“This has been a transformative period for our company,” said Geordan Pursglove, who became LIXTE’s new Chairman and Chief Executive Officer in June. “Momentum has been energized on several fronts, including securing essential funding to support our ongoing clinical trials, and to pursue long-term growth opportunities to enhance shareholder value.”","length":350,"tagName":"p"},{"type":"text","content":"Added Bas van der Baan, President and Chief Scientific Officer, “We are especially proud of the recent publication in a leading medical journal, Nature, further validating the promise of our proprietary compound, LB-100, to treat ovarian and colorectal cancer. The recent formation of our medical advisory committee marks yet another strat...